A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma
Phase 2
- Conditions
- aggressive lymphoma
- Registration Number
- JPRN-UMIN000048724
- Lead Sponsor
- the Hematological Malignancy Clinical Study Group
- Brief Summary
The CR rate was 65.5% (95% confidence interval, 45.7~82.1%). The 3-year failure-free and overall survival rates were 54.1% and 53.9%, respectively.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
any other malignancies, mental illness, myocardial infarction or angina history, central nervous system infiltration, uncontrollable diabetes, human immunodeficiency virus infection, hepatitis B virus surface antigen, and/or hepatitis C virus antibody positivity were excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method